ERT Survey Reveals Challenges and Innovations within CNS Clinical Trials

Results demonstrate adoption of virtual and wearable technologies to increase effectiveness of CNS studies

PHILADELPHIA – February 25, 2021 – ERT, the global leader in clinical endpoint data collection, today released a new report, Innovation Frontiers in CNS Research, which analyzes the results of a recent industry survey on central nervous system (CNS) clinical trials. The report reveals key challenges for sponsors and study teams, as well as the innovations they are implementing to address them, including wearable technologies and virtual trial solutions.

CNS diseases include all manner of neurological and psychiatric disorders and conditions and represent one of the largest economic, social and capital burdens worldwide of any disease group. In fact, one in five U.S. adults (51.5 million) and one in six U.S. adolescents (7.7 million) are living with some type of CNS condition.1,2 The prevalence of CNS disorders indicates a significant need for continued therapeutic innovation. However, unique challenges specific to the therapeutic area, such as the many unknowns about the diseases themselves, have challenged progress in the search for effective treatments and cures.

ERT Survey Reveals Challenges and Innovations within CNS Clinical Trials

Fielded in the fourth quarter of 2020, the survey seeks to better understand how a cross-section of key industry professionals from leading pharmaceutical companies are adopting and using new innovations within CNS trials to address challenges specific to this therapeutic area. Key findings include: 

  • What keeps you up at night?: When asked to rank the issues keeping them up at night when conducting a CNS trial, 80% of respondents cited budget management among their top two concerns. 
  • Current or planned use of wearables: 80% of survey respondents have used, or are planning to use, wearable technology in their CNS Trials.
  • Current adoption of virtual trial technologies in CNS trials: More than one third of respondents report running fully virtual, or decentralized, CNS trials or a hybrid model featuring some virtual solutions. 

“CNS therapies represent a pressing societal need. Manufacturers are looking to innovative patient centric technologies that also offer patients improved convenience like telehealth and at-home data collection to accelerate and improve trial execution” said Jim Mahon, Executive Vice President, Chief Product, Strategy and Marketing Officer, ERT. 

To learn more, download the report, Innovation Frontiers in CNS Research, which includes detailed survey findings and strategies for operationalizing and scaling trial innovations.

ERTについて

ERT is a global data and technology company that minimizes uncertainty and risk in clinical trials so that its customers can move ahead with confidence. ERTは50年近い臨床経験および治療経験を有しており、実際に機能することの知識と今後の出来事の予測を調和させて、基準を低下させることなく適応することができます。

For more information, go to ert.com or follow us on LinkedIn and Twitter.

ERT Media Contact:
Terry Stanulis
Director, Thought Leadership and Public Relations
terry.stanulis@ert.com
+1 862-288-0329

シェアする